Acquired Aplastic Anemia Market Research Report- Forecast till 2027

Acquired Aplastic Anemia Market Information: By Type (Moderate Aplastic Anemia), By Diagnosis (Bone Marrow Biopsy, CT Scan), Treatment (Bone Marrow Transplantation, Immunosuppressive Therapies), End User (Hospitals & Clinics) - Forecast till 2027

ID: MRFR/Pharma/3249-HCR | February 2021 | Region: Global | 115 Pages         

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Acquired Aplastic Anemia Market, by Type

6.1 Introduction

6.2 Moderate Aplastic Anemia

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Severe Aplastic Anemia

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Very Severe Aplastic Anemia

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Acquired Aplastic Anemia Market, by Diagnosis

7.1 Introduction

7.2 Bone marrow biopsy

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 X-rays

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Computed tomography (CT) scans

7.4.1 Market Estimates & Forecast, 2020-2027

8. Global Acquired Aplastic Anemia Market, by Treatment

8.1 Introduction

8.2 Bone marrow transplantation

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Immunosuppressive therapies

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Acquired Aplastic Anemia Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Research centers

9.3.1 Market Estimates & Forecast, 2020-2027

10. Global Acquired Aplastic Anemia Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Pfizer Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Bayer AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Novo Nordisk AS

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Shire

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 SOBI

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Octapharma

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 CSL Limited

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Acquired Aplastic Anemia Industry Synopsis, 2020-2027

Table 2 Global Acquired Aplastic Anemia Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Acquired Aplastic Anemia Market by Region, 2020-2027, (USD Million)

Table 4 Global Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 5 Global Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 6 Global Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 7 Global Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 8 North America Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 9 North America Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 10 North America Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 11 North America Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 12 US Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 13 US Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 14 US Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 15 US Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 16 Canada Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 17 Canada Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 18 Canada Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 19 Canada Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 20 South America Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 21 South America Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 22 South America Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 23 South America Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 24 Europe Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 25 Europe Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Europe Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 27 Europe Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 28 Western Europe Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 29 Western Europe Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 30 Western Europe Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 31 Western Europe Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 32 Eastern Europe Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 33 Eastern Europe Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 34 Eastern Europe Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 35 Eastern Europe Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 36 Asia Pacific Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 37 Asia Pacific Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 38 Asia Pacific Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 39 Asia Pacific Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

Table 40 Middle East & Africa Acquired Aplastic Anemia Market by Types, 2020-2027, (USD Million)

Table 41 Middle East & Africa Acquired Aplastic Anemia Market by Diagnosis, 2020-2027, (USD Million)

Table 42 Middle East & Africa Acquired Aplastic Anemia Market by Treatment, 2020-2027, (USD Million)

Table 43 Middle East & Africa Acquired Aplastic Anemia Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Acquired Aplastic Anemia Market

Figure 3 Segmentation Market Dynamics for Acquired Aplastic Anemia Market

Figure 4 Global Acquired Aplastic Anemia Market Share, by Diagnosis 2020

Figure 5 Global Acquired Aplastic Anemia Market Share, by Treatment 2020

Figure 6 Global Acquired Aplastic Anemia Market Share, by End Users, 2020

Figure 7 Global Acquired Aplastic Anemia Market Share, by Region, 2020

Figure 8 North America Acquired Aplastic Anemia Market Share, by Country, 2020

Figure 9 Europe Acquired Aplastic Anemia Market Share, by Country, 2020

Figure 10 Asia Pacific Acquired Aplastic Anemia Market Share, by Country, 2020

Figure 11 Middle East & Africa Acquired Aplastic Anemia Market Share, by Country, 2020

Figure 12 Global Acquired Aplastic Anemia Market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer Inc.: Key Financials

Figure 14 Pfizer Inc.: Segmental Revenue

Figure 16 Pfizer Inc.: Geographical Revenue

Figure 17 Bayer AG: Key Financials

Figure 18 Bayer AG: Segmental Revenue

Figure 19 Bayer AG: Geographical Revenue

Figure 20 Novo Nordisk AS: Key Financials

Figure 21 Novo Nordisk AS: Segmental Revenue

Figure 22 Novo Nordisk AS: Geographical Revenue

Figure 23 Shire: Key Financials

Figure 24 Shire: Segmental Revenue

Figure 25 Shire: Geographical Revenue

Figure 26 SOBI: Key Financials

Figure 27 SOBI: Segmental Revenue

Figure 28 SOBI: Geographical Revenue

Figure 29 Octapharma: Key Financials

Figure 30 Octapharma: Segmental Revenue

Figure 31 Octapharma: Geographical Revenue

Figure 32 CSL Limited: Key Financials

Figure 33 CSL Limited: Segmental Revenue

Figure 34 CSL Limited: Geographical Revenue

Acquired Aplastic Anemia Market Speak to Analyst Request a Free Sample

Acquired Aplastic Anemia Market Scenario


Acquired aplastic anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components.

Aplastic anemia has two manifestations, i.e. Acquired aplastic anemia and inherit aplastic anemia Acquired aplastic anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia. Various causes of acquired aplastic anemia includes toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy-treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause acquired aplastic anemia.

The acquired aplastic anemia market growth is majorly attributed to the increasing prevalence of the blood disorders, rising funding, healthcare insurance coverage, and awareness programs for blood disorders.

According to the 2014 Annual Global Survey of the World Federation of Hemophilia (WFH), the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with Von Willebrand disease, and 1,123 with other blood disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years

A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia and most dominant in male patients is 1: 5000 to 10,000. Whereas, the prevalence rate of hemophilia B is 1: 34,500 male patients.

Moreover, advancing technology in medical devices is adding fuel to the growth of the market. Furthermore, increasing prevalence of cancer also drives the market growth.

However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

The global acquired aplastic anemia market is expected to grow at a CAGR of 7.6 % during the forecast period 2017-2023.

 Figure: Global Acquired Aplastic Anemia Market, By Region Market Share, 2016 (%) Acquired Aplastic Anemia Market


               Sources: Annual reports, Press release, White paper, Company presentation


Acquired Aplastic Anemia Market Segmentations


The global acquired aplastic anemia market is segmented on the basis of types, by diagnosis, by treatment, and by end user.


On the basis of type, it is segmented into moderate aplastic anemia, severe aplastic anemia, and very severe aplastic anemia.  


On the basis of diagnosis, it is segmented into bone marrow biopsy, X-rays, computed tomography (CT) scans, and others.  


On the basis of treatment, it is segmented into bone marrow transplantation, immunosuppressive therapies, and others.


On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.


Acquired Aplastic Anemia Market Regional Analysis


The Americas dominate the global acquired aplastic anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the global acquired aplastic anemia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.


Asia Pacific is the fastest growing acquired aplastic anemia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acquired aplastic anemia in the region.


On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. 


Acquired Aplastic Anemia Market Key Players


Some of key the players in the acquired aplastic anemia market are 



  • Pfizer Inc. (U.S.)

  • Bayer AG (Germany)

  • Novo Nordisk AS (Dernmark)

  • Shire (Republic of Ireland)

  • SOBI (Sweden)

  • Octapharma (Switzerland)

  • CSL Limited (Australia)

  • Amgen Inc.

  • GlaxoSmithKline plc.

  • Bluebird bio.


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities 


 


Research Methodology Acquired Aplastic Anemia Market-


Sources: Annual reports, Press release, White paper, and Company presentation



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2017-2023: 7.6%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Diagnosis, Treatment, And End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), CSL Limited (Australia), Amgen Inc., GlaxoSmithKline plc., and Bluebird bio.
  Key Market Opportunities

  • High healthcare spending
  • Increasing government support for research & development
  •   Key Market Drivers

  • Increasing prevalence of the blood disorders
  • Rising funding
  • Healthcare insurance coverage
  • Awareness programs for blood disorders


  • Speak to Analyst Ask for Customization